Expect significant price pressure as the IPO shares begin trading (likely within days). The dual effective registration (S-1 for new shares + S-3 for existing holder resale) creates a massive overhang that will likely suppress the stock. Monitor for pricing and lock-up terms; any insider selling after the IPO could accelerate declines.
Price Chart
Executive Summary
AEON Biopharma's S-1 IPO registration became effective on July 13, 2026, allowing the company to proceed with a highly dilutive public offering of up to $45.3M against a current market cap of ~$8M. Simultaneously, the S-3 shelf registration for resale of up to 51.3M shares (from existing holders) also went effective, creating a dual dilution overhang for a pre-revenue clinical-stage biotech with no approved products.
Key Facts
- S-1 IPO registration declared effective; company can now sell shares to the public.
- Total registered offering amount is $45.3M, more than 5x the current $8M market cap.
- S-3 shelf for resale of up to 51,292,953 shares from existing holders also effective—no proceeds to company.
- Company is pre-revenue clinical-stage biotech (Pharmaceutical Preparations) with no approved products.
- Prior S-1/A analysis flagged this as highly dilutive, and the effectiveness removes remaining uncertainty.
Financial Impact
Up to $45.3M in new shares to be issued vs $8M market cap—over 5x dilution; additional overhang from 51.3M resale shares on S-3 shelf.
Risk Factors
- Extreme dilution: offerings total ~$45.3M from S-1 plus 51.3M shares on S-3 against tiny $8M market cap.
- Pre-revenue status with no drug revenue—company relies on capital markets for survival.
- Risk of IPO failure or pricing well below assumed levels due to market conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002285 |
| Document: 9999999995-26-002285-index.html | 9999999995-26-002285 |
| Document: 9999999995-26-002285.txt | 9999999995-26-002285 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | — | awaiting T+5 | — | — |
Oct 23, 2026 3d ago | 8-K | $0.2399 | awaiting T+5 | — | $0.2400 (+0.04%) |
Sep 30, 2026 26d ago | 8-K | $0.3000 $0.3110 | ▲ +3.67% | ▲ +1.75% | $0.2400 (−20.00%) |
Aug 21, 2026 9w ago | 3 | $0.1974 $0.2959 | ▲ +49.90% | ▲ +49.43% | $0.2400 (+21.58%) |
Aug 19, 2026 9w ago | Press Release | $0.1980 $0.2515 | ▲ +27.02% | ▲ +27.41% | $0.2400 (+21.21%) |
Aug 12, 2026 10w ago | Press Release | $0.2706 $0.1931 | ▼ −28.64% | ▼ −26.68% | $0.2400 (−11.31%) |
Jul 23, 2026 13w ago | 8-K | $0.2507 $0.2552 | ▼ −1.79% | ▼ −1.42% | $0.2400 (+4.27%) |
Jul 15, 2026 14w ago | 8-K | $0.2974 $0.2600 | ▲ +12.58% | ▲ +10.91% | $0.2400 (+19.30%) |
Jul 15, 2026 14w ago | 424B4 | $0.2997 $0.2752 | ▲ +8.17% | ▲ +7.19% | $0.2400 (+19.92%) |
Jul 14, 2026 14w ago | EFFECT | $0.3570 $0.2890 | ▲ +19.05% | ▲ +17.75% | $0.2400 (+32.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers